Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine
Abstract Drug screening of primary tumor cells directly assesses the drug efficacy on specific tumors, promoting personalized cancer treatment. The application of a microfluidic platform has realized drug screening using a limited amount of biopsy samples for cancer precision medicine. However, all...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202503131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059544485429248 |
|---|---|
| author | Wenhao Hui Ka‐Meng Lei Yingying Liu Xinru Huang Yunlong Zhong Xiaojun Chen Mingji Wei Jie Yan Ren Shen Pui‐In Mak Rui P. Martins Shuhong Yi Ping Wang Yanwei Jia |
| author_facet | Wenhao Hui Ka‐Meng Lei Yingying Liu Xinru Huang Yunlong Zhong Xiaojun Chen Mingji Wei Jie Yan Ren Shen Pui‐In Mak Rui P. Martins Shuhong Yi Ping Wang Yanwei Jia |
| author_sort | Wenhao Hui |
| collection | DOAJ |
| description | Abstract Drug screening of primary tumor cells directly assesses the drug efficacy on specific tumors, promoting personalized cancer treatment. The application of a microfluidic platform has realized drug screening using a limited amount of biopsy samples for cancer precision medicine. However, all the techniques face an inevitable issue of not all the primary tumor cells being cancer cells. Here, a system is introduced that integrates single‐cell identification and drug screening on one semiconductor chip so that both drug efficacy on cancer cells and drug toxicity on noncancerous cells can be obtained simultaneously. An integrated circuit is built on the semiconductor chip for single‐cell electric impedance sensing (IC‐ECIS) of ultra‐weak signals for distinguishing cancer cells from noncancerous cells without affecting cell vitality. Single‐cell identification is validated using breast, lung, and liver cell lines as well as liver cancer specimens from clinical patients. The accuracy on commercial cell lines is ≈80%, and the diagnostic results of tumor tissues are consistent with clinical pathology results. Drug screening is run on the same chip after single cell identification for dual evaluation of drug efficacy and toxicity in both breast cancer models and clinical liver cancer patients. The on‐chip drug screening is confirmed with off‐chip counterpart experiments in breast cell lines. The effectiveness or ineffectiveness of a drug screened on the IC‐ECIS chip demonstrated consistency in the presence or absence of specific mutations in the drug‐related genes determined via exome sequencing of individual liver tumors, validating the method for precision medicine. |
| format | Article |
| id | doaj-art-b9e7250603fe4f2d9300298830bdeab1 |
| institution | DOAJ |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-b9e7250603fe4f2d9300298830bdeab12025-08-20T02:50:52ZengWileyAdvanced Science2198-38442025-07-011228n/an/a10.1002/advs.202503131Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision MedicineWenhao Hui0Ka‐Meng Lei1Yingying Liu2Xinru Huang3Yunlong Zhong4Xiaojun Chen5Mingji Wei6Jie Yan7Ren Shen8Pui‐In Mak9Rui P. Martins10Shuhong Yi11Ping Wang12Yanwei Jia13State Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauLiver Transplantation Center The Third Affiliated Hospital Sun Yat‐Sen University Guangzhou 510000 ChinaDepartment of Hepatobiliary Surgery The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510000 ChinaState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauElectrical and Information Engineering Jiangsu University Zhenjiang 212000 ChinaDepartment of Physics National University of Singapore Singapore 546080 SingaporeState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauLiver Transplantation Center The Third Affiliated Hospital Sun Yat‐Sen University Guangzhou 510000 ChinaDepartment of Hepatobiliary Surgery The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510000 ChinaState Key Laboratory of Analog and Mixed‐Signal VLSI Institute of Microelectronics University of Macau Taipa 999078 MacauAbstract Drug screening of primary tumor cells directly assesses the drug efficacy on specific tumors, promoting personalized cancer treatment. The application of a microfluidic platform has realized drug screening using a limited amount of biopsy samples for cancer precision medicine. However, all the techniques face an inevitable issue of not all the primary tumor cells being cancer cells. Here, a system is introduced that integrates single‐cell identification and drug screening on one semiconductor chip so that both drug efficacy on cancer cells and drug toxicity on noncancerous cells can be obtained simultaneously. An integrated circuit is built on the semiconductor chip for single‐cell electric impedance sensing (IC‐ECIS) of ultra‐weak signals for distinguishing cancer cells from noncancerous cells without affecting cell vitality. Single‐cell identification is validated using breast, lung, and liver cell lines as well as liver cancer specimens from clinical patients. The accuracy on commercial cell lines is ≈80%, and the diagnostic results of tumor tissues are consistent with clinical pathology results. Drug screening is run on the same chip after single cell identification for dual evaluation of drug efficacy and toxicity in both breast cancer models and clinical liver cancer patients. The on‐chip drug screening is confirmed with off‐chip counterpart experiments in breast cell lines. The effectiveness or ineffectiveness of a drug screened on the IC‐ECIS chip demonstrated consistency in the presence or absence of specific mutations in the drug‐related genes determined via exome sequencing of individual liver tumors, validating the method for precision medicine.https://doi.org/10.1002/advs.202503131cell impedancedrug screeningintegrated circuit (IC)precision medicinesingle cell |
| spellingShingle | Wenhao Hui Ka‐Meng Lei Yingying Liu Xinru Huang Yunlong Zhong Xiaojun Chen Mingji Wei Jie Yan Ren Shen Pui‐In Mak Rui P. Martins Shuhong Yi Ping Wang Yanwei Jia Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine Advanced Science cell impedance drug screening integrated circuit (IC) precision medicine single cell |
| title | Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine |
| title_full | Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine |
| title_fullStr | Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine |
| title_full_unstemmed | Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine |
| title_short | Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine |
| title_sort | identification and drug screening of single cells from human tumors on semiconductor chip for cancer precision medicine |
| topic | cell impedance drug screening integrated circuit (IC) precision medicine single cell |
| url | https://doi.org/10.1002/advs.202503131 |
| work_keys_str_mv | AT wenhaohui identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT kamenglei identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT yingyingliu identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT xinruhuang identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT yunlongzhong identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT xiaojunchen identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT mingjiwei identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT jieyan identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT renshen identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT puiinmak identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT ruipmartins identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT shuhongyi identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT pingwang identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine AT yanweijia identificationanddrugscreeningofsinglecellsfromhumantumorsonsemiconductorchipforcancerprecisionmedicine |